Benzinga | Sep 11, 2020 08:19AM EDT

Wedbush Upgrades Sage Therapeutics to Outperform, Raises Price Target to $65

Wedbush upgrades Sage Therapeutics (NASDAQ:SAGE) from Neutral to Outperform and raises the price target from $40 to $65.